Embattled drug testing firm Huntingdon Life Sciences has been sold, it emerged today.

Huntingdon, the target of sustained opposition - some of it violent - from animal welfare campaigners, has been bought by US group Life Sciences Research in an all-share deal.

LSR was set up last year by a group of US investors with the express intention of buying the controversial firm.

An offer was first made in October and today Huntingdon said LSR had received acceptances representing 89.5% of the share capital, enough to make the offer unconditional.

Huntingdon's market listing will now move to the New York Stock Exchange - its London listing will be cancelled with effect from January 24, although its site in Cambridgeshire will be unaffected.

Huntingdon tests a range of drugs and products on animals that include dogs, cats and baboons.

The group and its backers have long-been the target of animal welfare groups, who are opposed to its use of animals.

In January last year Huntingdon was bought to its knees after a string of backers withdrew support from the venture.

But it was saved at the last minute after US investment group and shareholder Stephens issued an £11 million loan.

On Wednesday, Stephens revealed it was selling its investment and 15.7% stake in Huntingdon, but stressed that it was not because of the campaign.

Warren Stephens, the group's president, had his New York home vandalised last week and other staff at Stephens have been caught up in the protests over recent months.